Difference between revisions of "Team:Paris Bettencourt/Sustainability/Acceptance"
Line 9: | Line 9: | ||
<div class="column-left"> | <div class="column-left"> | ||
− | <p>Setting up our project, we involved local Indian citizens and authorities in India to understand their needs and how a | + | <p>Setting up our project, we involved local Indian citizens and expert authorities in India to understand their needs and how a synthetic biology approach answer them in an accepted way. They shared with us how they perceive our work and what were their concerns, comments and questions. Our project has largely benefited from these exchanges. </p> |
</div> | </div> | ||
Line 18: | Line 18: | ||
<br> | <br> | ||
− | <h1 class="date two"> | + | <h1 class="date two"> Authorities and Experts : </h1> |
<div class="column-left"> | <div class="column-left"> | ||
− | + | We exchanged with lawmakers and food safety authorities to get their views on our project and tune it accrodingly. | |
− | + | ||
− | A. K. Sharma, the consultant of the FSSAI on the behalf of the Chairperson and CEO of FSSAI. | + | <b>* FSSAI, the Food Safety and Standard Authority in India </b> |
− | Sunita Grover, | + | Contact person: Dr. A. K. Sharma, the consultant of the FSSAI on the behalf of the Chairperson and CEO of FSSAI. |
− | Institute | + | Advice: Choose the right microorganisms so they can survive and work togethe, along with the use of critical genes for the vitamins pathways. Concerning the law, he said that there is currently no authorisation for GMO microorganisms in the Indian Food regulation and if we want to have our product in India, the safety needs to be established. |
− | + | ||
− | + | Contact person: Dr. Sunita Grover, principal scientist and head of the Dairy Microbiology Division at the National Dairy Research | |
− | use of genetically modified bacteria. | + | Institute |
− | living in fermentation batter | + | Advice: Use food grade vector system to make sure our product is safe for consumption and to reduce issues arising form the |
− | concern is safety. | + | use of genetically modified bacteria. She had concerns about the compatibility of the different species |
+ | living in fermentation batter. To finish, her major | ||
+ | concern is safety. our project needs to undergo phase I and II trials, to assess safety and scientifically proven health benefits. | ||
+ | She was surprised and really enthusiastic towards the project because malnutrition is a serious problem in India and many children suffer from it | ||
+ | our project</p> | ||
</div> | </div> | ||
<div class="column-right"> | <div class="column-right"> | ||
− | + | Contact person: Prof. Samir K. Brahmachari, the former director of the Council of Scientific and Industrial Research in India. | |
+ | |||
+ | Advice: Regarding the law, there is no GM microorganisms that are allowed because of the use of antibiotic markers that makes them unsafe to eat. But for him if we can add a safe vitamin pathway on already eaten bacteria (lactic bacteria for example) that will be sterilized but producing enough vitamin to fortify the food, it should be possible. It is not impossible that regulatory issues can undergo changes. Concerning the GMO debate in Europe and India, the main points are different: in India, people don't want GMO to be associated with farmers, they don't want them to be dependent and no one want a monopoly of a particular plant. These issues don't apply to our project for Samir Brahmachari, but labelling would be an problem: the use of our product only depends on people's wish. If people find it beneficial and safe, they would take it. To continue, an accelerated evolution can be more acceptable for a project like ours for the GMO regulation. Also, since our project doesn't imply a big company producing and giving a product, it is more likely to work and be more accepted, as well as the way we want to implement it (give power to people, let them have their own "mini-lab" and produce their bacteria and yeast for their consumption) according to him. | ||
+ | |||
+ | Prof. Brahmachari visited us this summer and participated to our first workshop. We went to meet him again at the 2nd Annual Open Source Pharma Conference in Frankfurt, Germany at the end of the summer. | ||
</p> | </p> | ||
</div> | </div> |
Revision as of 02:19, 19 September 2015